References
- Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. New England Journal of Medicine 1998; 339: 1506–1514
- Smith R S, Chen Q, Hudson M M, Link M P, Kun L, Weinstein H, Billett A, Marcus K J, Tarbell N J, Donaldson S S. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. Journal of Clinical Oncology 2003; 21: 2026–2033
- Longo D L, Duffey P L, Young R C, Hubbard S M, Ihde D C, Glatstein E, et al. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability of cure. Journal of Clinical Oncology 1992; 10: 210–218
- Horning S J, Chao N J, Negrin R S, Hoppe R T, Long G D, Hu W W, et al. High-dose therapy and autologous hematopoeitic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801–813
- Seymour J F, Talpaz M, Kurzrock R. Response duration and recovery of CD4 + lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia 1997; 11: 42–47
- Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. Journal of Clinical Oncology 1999; 17: 3117–3121
- Tsimberidou A M, Giles F, Duvic M, Fayad L, Kurzrock R. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer 2004; 100: 342–349
- Monfardini S, Sorio R, Cavalli F, Cerny T H, Van Glabbeke M, Kaye S, Smyth J F. Pentostatin (2′-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group. Oncology 1996; 53: 163–168
- Spiers A S, Ruckdeschel J C, Horton J. Effectiveness of pentostatin (2′-deoxycoformycin) in refractory lymphoid neoplasms. Scandinavian Journal of Haematology 1984; 32: 130–134
- Cummings F J, Kim K, Neiman R S, Comis R L, Oken M M, Weitzman S A, Mann R B, O'Connell M J. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. Journal of Clinical Oncology 1991; 9: 565–571
- Grever M R, Coleman M S, Gray D P, Malspeis D, Balcerzak S P, Neidhart J A. Definition of safe, effective dosing regimen of 2′-deoxycoformycin with biochemical investigation. Cancer Treatment Symposium 1984; 2: 43–48